Published in Adv Drug Deliv Rev on April 24, 2008
Targeting of drugs and nanoparticles to tumors. J Cell Biol (2010) 4.07
Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci U S A (2013) 1.83
Factors determining antibody distribution in tumors. Trends Pharmacol Sci (2008) 1.80
Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res (2011) 1.62
The development of immunoconjugates for targeted cancer therapy. Nat Rev Clin Oncol (2014) 1.49
Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J (2009) 1.48
Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol (2012) 1.33
Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids. Mol Cancer Ther (2008) 1.32
A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel (2009) 1.29
A systems approach for tumor pharmacokinetics. PLoS One (2011) 1.27
Advances in the formation, use and understanding of multi-cellular spheroids. Expert Opin Biol Ther (2012) 1.25
Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications. Curr Pharm Des (2010) 1.23
Improving the efficacy of Photoimmunotherapy (PIT) using a cocktail of antibody conjugates in a multiple antigen tumor model. Theranostics (2013) 1.20
Biotechnological applications of recombinant single-domain antibody fragments. Microb Cell Fact (2011) 1.16
Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm (2009) 1.16
Increased tumor homing and tissue penetration of the filamentous plant viral nanoparticle Potato virus X. Mol Pharm (2012) 1.13
Multizone paper platform for 3D cell cultures. PLoS One (2011) 1.09
Potato virus X as a novel platform for potential biomedical applications. Nano Lett (2010) 1.08
A mechanistic compartmental model for total antibody uptake in tumors. J Theor Biol (2012) 1.07
Combinatorial peptide libraries: mining for cell-binding peptides. Chem Rev (2013) 1.07
The history of monoclonal antibody development - Progress, remaining challenges and future innovations. Ann Med Surg (Lond) (2014) 1.06
Viral nanoparticles as platforms for next-generation therapeutics and imaging devices. Nanomedicine (2010) 1.04
Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs (2012) 1.04
Quantitating antibody uptake in vivo: conditional dependence on antigen expression levels. Mol Imaging Biol (2011) 1.03
ADME of antibody-maytansinoid conjugates. AAPS J (2012) 1.03
The Impact of Aspect Ratio on the Biodistribution and Tumor Homing of Rigid Soft-Matter Nanorods. Adv Healthc Mater (2015) 1.01
Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities. Crit Rev Biomed Eng (2012) 1.00
Multicolor fluorescent intravital live microscopy (FILM) for surgical tumor resection in a mouse xenograft model. PLoS One (2009) 0.99
Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors. Mol Cancer Ther (2014) 0.98
Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties. J Biol Chem (2010) 0.98
Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J Biol Chem (2012) 0.96
Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment. EJNMMI Res (2011) 0.94
A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy. Nat Commun (2015) 0.94
Transferrin-mediated targeting of bacteriophage HK97 nanoparticles into tumor cells. Nanomedicine (Lond) (2011) 0.93
Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn (2014) 0.93
Platform for high-throughput testing of the effect of soluble compounds on 3D cell cultures. Anal Chem (2013) 0.92
Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells. Mol Cancer Ther (2010) 0.91
A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate. AAPS J (2014) 0.89
Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling. J Pharmacokinet Pharmacodyn (2012) 0.88
Non-invasive longitudinal imaging of tumor progression using an (111)indium labeled CXCR4 peptide antagonist. Am J Nucl Med Mol Imaging (2011) 0.87
Development of copper based drugs, radiopharmaceuticals and medical materials. Biometals (2012) 0.87
Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes. Neoplasia (2013) 0.87
Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases. J Control Release (2012) 0.85
Chemically modified antibodies as diagnostic imaging agents. Curr Opin Chem Biol (2010) 0.85
A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density. PLoS One (2013) 0.85
The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Adv Drug Deliv Rev (2015) 0.84
Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates. Pharm Res (2014) 0.84
Antigen shedding may improve efficiencies for delivery of antibody-based anticancer agents in solid tumors. Cancer Res (2012) 0.83
Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design. AAPS J (2016) 0.82
Multichannel imaging to quantify four classes of pharmacokinetic distribution in tumors. J Pharm Sci (2014) 0.82
T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cell. Oncotarget (2014) 0.81
Quantum dot loaded immunomicelles for tumor imaging. BMC Med Imaging (2010) 0.81
Dose dependence of intratumoral perivascular distribution of monoclonal antibodies. J Pharm Sci (2011) 0.81
Nanotechnology for energy-based cancer therapies. Am J Cancer Res (2011) 0.81
Molecular Imaging of Pancreatic Cancer with Antibodies. Mol Pharm (2015) 0.80
Monovalent IgG4 molecules: immunoglobulin Fc mutations that result in a monomeric structure. MAbs (2013) 0.80
Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells. MAbs (2012) 0.80
Practical ImmunoPET radiotracer design considerations for human immune checkpoint imaging. J Nucl Med (2016) 0.80
Nanoparticle amplification via photothermal unveiling of cryptic collagen binding sites. J Mater Chem B Mater Biol Med (2013) 0.79
Targeted erythropoietin selectively stimulates red blood cell expansion in vivo. Proc Natl Acad Sci U S A (2016) 0.78
Quantitative measurement of the target-mediated internalization kinetics of biopharmaceuticals. Pharm Res (2014) 0.78
Effect of antigen shedding on targeted delivery of immunotoxins in solid tumors from a mathematical model. PLoS One (2014) 0.78
From transformation to metastasis: deconstructing the extracellular matrix in breast cancer. Cancer Metastasis Rev (2016) 0.78
Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1). AAPS J (2016) 0.77
Mathematical framework for activity-based cancer biomarkers. Proc Natl Acad Sci U S A (2015) 0.77
HLA-B27-Homodimer-Specific Antibody Modulates the Expansion of Pro-Inflammatory T-Cells in HLA-B27 Transgenic Rats. PLoS One (2015) 0.77
EpCAM as multi-tumour target for near-infrared fluorescence guided surgery. BMC Cancer (2016) 0.77
A 45-Amino-Acid Scaffold Mined from the PDB for High-Affinity Ligand Engineering. Chem Biol (2015) 0.77
Combination Radioimmunotherapy Approaches and Quantification of Immuno-PET. Nucl Med Mol Imaging (2016) 0.76
Design and Synthesis of Near-Infrared Peptide for in Vivo Molecular Imaging of HER2. Bioconjug Chem (2015) 0.76
Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy. AAPS J (2016) 0.76
Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions. Cancers (Basel) (2017) 0.75
Visualizing epithelial expression of EGFR in vivo with distal scanning side-viewing confocal endomicroscope. Sci Rep (2016) 0.75
In vivo fluorescence imaging of hepatocellular carcinoma xenograft using near-infrared labeled epidermal growth factor receptor (EGFR) peptide. Biomed Opt Express (2016) 0.75
CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells. Oncotarget (2016) 0.75
Tracking Antibody Distribution with Near-Infrared Fluorescent Dyes: Impact of Dye Structure and Degree of Labeling on Plasma Clearance. Mol Pharm (2017) 0.75
Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged Affibody-based tracer to estimate the specific uptake. EJNMMI Res (2016) 0.75
Spatial Modeling of Drug Delivery Routes for Treatment of Disseminated Ovarian Cancer. Cancer Res (2015) 0.75
Role of vascular normalization in benefit from metronomic chemotherapy. Proc Natl Acad Sci U S A (2017) 0.75
Diffusion and Uptake of Tobacco Mosaic Virus as Therapeutic Carrier in Tumor Tissue: Effect of Nanoparticle Aspect Ratio. J Phys Chem B (2016) 0.75
Antibody Drug Conjugates: Preclinical Considerations. AAPS J (2015) 0.75
In vitro microfluidic models of tumor microenvironment to screen transport of drugs and nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2017) 0.75
Targeting insulin receptor in breast cancer using small engineered protein scaffolds. Mol Cancer Ther (2017) 0.75
A novel individual-cell-based mathematical model based on multicellular tumour spheroids for evaluating doxorubicin-related delivery in avascular regions. Br J Pharmacol (2017) 0.75
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 15.43
Drug penetration in solid tumours. Nat Rev Cancer (2006) 9.80
Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A (1998) 7.78
Engineered antibody fragments and the rise of single domains. Nat Biotechnol (2005) 6.96
Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nat Biotechnol (2002) 6.68
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res (1995) 6.21
Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol (2005) 5.80
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res (2004) 5.65
Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A (1996) 5.04
Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci (1995) 4.83
Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol (2004) 4.47
Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci (2004) 4.28
Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst (2006) 4.27
Pathophysiological consequences of VEGF-induced vascular permeability. Nature (2005) 4.08
Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng (1999) 3.64
Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res (2007) 3.45
Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med (2000) 3.34
General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn (2001) 3.21
Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res (1992) 3.09
Microvascular permeability of normal and neoplastic tissues. Microvasc Res (1986) 3.04
Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A (2001) 2.96
Induction of a bystander mutagenic effect of alpha particles in mammalian cells. Proc Natl Acad Sci U S A (2000) 2.92
High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res (2001) 2.90
Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res (1987) 2.85
Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res (1989) 2.82
Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol (1986) 2.82
The physiology of the lymphatic system. Adv Drug Deliv Rev (2001) 2.72
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell (2004) 2.60
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol (2005) 2.55
124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med (2003) 2.44
Structural determinants of glomerular permeability. Am J Physiol Renal Physiol (2001) 2.38
Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res (1998) 2.38
The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol (2002) 2.27
Domain antibodies: proteins for therapy. Trends Biotechnol (2003) 2.15
Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol (1996) 2.08
Extravascular diffusion in normal and neoplastic tissues. Cancer Res (1984) 2.04
Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol (1999) 2.02
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci U S A (2005) 2.00
ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem (1999) 1.98
Direct in vivo measurement of targeted binding in a human tumor xenograft. Proc Natl Acad Sci U S A (1997) 1.95
Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res (2005) 1.88
Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res (2003) 1.87
A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med (1990) 1.85
Target-mediated drug disposition and dynamics. Biochem Pharmacol (2006) 1.85
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res (2005) 1.84
Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn (2007) 1.82
Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Acad Sci U S A (1999) 1.82
Numerical selection of optimal tumor imaging agents with application to engineered antibodies. Cancer Biother Radiopharm (2001) 1.81
Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol (2003) 1.81
Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res (1992) 1.81
Factors determining antibody distribution in tumors. Trends Pharmacol Sci (2008) 1.80
Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci U S A (2006) 1.79
Pharmacokinetic comparison of direct antibody targeting with pretargeting protocols based on streptavidin-biotin binding. J Nucl Med (1995) 1.78
Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med (2007) 1.69
Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability. Blood (2004) 1.69
Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res (1998) 1.68
Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res (1996) 1.67
Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm Res (2005) 1.65
Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther (1994) 1.64
Vascular permeability in a human tumour xenograft: molecular charge dependence. Br J Cancer (2000) 1.60
Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res (2007) 1.59
Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res (1998) 1.57
Further investigations of morpholino pretargeting in mice--establishing quantitative relations in tumor. Eur J Nucl Med Mol Imaging (2005) 1.48
Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res (1996) 1.47
Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. Cancer Res (1995) 1.46
Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res (1994) 1.45
Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. Microvasc Res (1991) 1.43
Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc Natl Acad Sci U S A (2002) 1.43
Role of tumor vascular architecture in nutrient and drug delivery: an invasion percolation-based network model. Microvasc Res (1996) 1.43
Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res (1996) 1.42
Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res (1991) 1.41
Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. Cancer Res (1990) 1.39
Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res (2006) 1.39
Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res (2006) 1.39
Microvascular studies on the origins of perfusion-limited hypoxia. Br J Cancer Suppl (1996) 1.38
Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging (2004) 1.36
Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem (2007) 1.36
Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol (2007) 1.32
Available volume fraction of macromolecules in the extravascular space of a fibrosarcoma: implications for drug delivery. Cancer Res (1999) 1.32
STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res (2003) 1.27
PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting. J Biol Chem (2006) 1.26
Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res (2006) 1.26
Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer (1998) 1.25
Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med (1996) 1.24
Penetration and binding of radiolabeled anti-carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular tumor spheroids. Cancer Res (1987) 1.22
Albumin mediates the transcytosis of myeloperoxidase by means of caveolae in endothelial cells. Proc Natl Acad Sci U S A (2004) 1.20
The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng Des Sel (2006) 1.20
Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft. Cancer Res (1996) 1.19
A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng (2005) 1.18
The pharmacology of monoclonal antibodies. Ann N Y Acad Sci (1987) 1.15
Cancer radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging (2005) 1.14
Transcytosis and catabolism of antibody. Immunol Res (2002) 1.14
Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin Cancer Res (2003) 1.12
Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells. Br J Cancer (2002) 1.11
Antibody-mediated cell cytotoxicity in a defined system: regulation by antigen, antibody, and complement. J Immunol (1976) 1.09
Isolating and engineering human antibodies using yeast surface display. Nat Protoc (2006) 5.02
Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat Biotechnol (2003) 3.34
Computational design of antibody-affinity improvement beyond in vivo maturation. Nat Biotechnol (2007) 2.92
Monovalent, reduced-size quantum dots for imaging receptors on living cells. Nat Methods (2008) 2.68
Yeast surface display for protein engineering and characterization. Curr Opin Struct Biol (2007) 2.38
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther (2009) 2.36
Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res (2003) 1.87
Stochastic kinetics of intracellular huntingtin aggregate formation. Nat Chem Biol (2006) 1.81
Factors determining antibody distribution in tumors. Trends Pharmacol Sci (2008) 1.80
Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med (2007) 1.69
Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling. J Mol Biol (2008) 1.64
Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc Natl Acad Sci U S A (2004) 1.62
Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. Proc Natl Acad Sci U S A (2008) 1.60
Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface. Structure (2013) 1.59
Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol (2009) 1.55
Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci U S A (2010) 1.46
Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display. J Mol Biol (2004) 1.43
Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. J Immunol Methods (2004) 1.39
High-affinity lamprey VLRA and VLRB monoclonal antibodies. Proc Natl Acad Sci U S A (2009) 1.35
Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol (2012) 1.33
Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids. Mol Cancer Ther (2008) 1.32
Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc Natl Acad Sci U S A (2008) 1.31
Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C. Protein Eng Des Sel (2004) 1.29
A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel (2009) 1.29
Engineering antibody affinity by yeast surface display. Methods Enzymol (2004) 1.26
A33 antigen displays persistent surface expression. Cancer Immunol Immunother (2008) 1.26
Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. Cancer Res (2008) 1.24
Selection of horseradish peroxidase variants with enhanced enantioselectivity by yeast surface display. Chem Biol (2007) 1.23
Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability. Cancer Immunol Immunother (2008) 1.23
Directed evolution of a secretory leader for the improved expression of heterologous proteins and full-length antibodies in Saccharomyces cerevisiae. Biotechnol Bioeng (2009) 1.23
Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem (2004) 1.23
Structural model of the mAb 806-EGFR complex using computational docking followed by computational and experimental mutagenesis. Structure (2006) 1.18
Shuffled antibody libraries created by in vivo homologous recombination and yeast surface display. Nucleic Acids Res (2004) 1.16
Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Eng Des Sel (2013) 1.11
Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display. J Mol Biol (2004) 1.10
Rapid method for measuring ScFv thermal stability by yeast surface display. Biotechnol Prog (2003) 1.09
Five birds, one stone: neutralization of α-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody. MAbs (2015) 1.06
Design criteria for engineering inorganic material-specific peptides. Langmuir (2005) 1.06
Highly avid magnetic bead capture: an efficient selection method for de novo protein engineering utilizing yeast surface display. Biotechnol Prog (2009) 1.05
Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Res (2013) 1.04
Highly L and D enantioselective variants of horseradish peroxidase discovered by an ultrahigh-throughput selection method. Proc Natl Acad Sci U S A (2008) 1.04
Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast. Proteins (2006) 1.03
Stability and CDR composition biases enrich binder functionality landscapes. J Mol Biol (2010) 1.03
Quantitative screening of yeast surface-displayed polypeptide libraries by magnetic bead capture. Biotechnol Prog (2002) 1.03
Interleukin 2 (IL-2) variants engineered for increased IL-2 receptor alpha-subunit affinity exhibit increased potency arising from a cell surface ligand reservoir effect. Mol Pharmacol (2004) 1.01
Integrating cell-level kinetic modeling into the design of engineered protein therapeutics. Nat Biotechnol (2005) 1.01
High-affinity CD25-binding IL-2 mutants potently stimulate persistent T cell growth. Biochemistry (2005) 1.01
Improved mutants from directed evolution are biased to orthologous substitutions. Protein Eng Des Sel (2006) 1.00
Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling. J Biol Chem (2011) 1.00
Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression. J Mol Biol (2012) 1.00
A flow cytometric assay for screening improved heterologous protein secretion in yeast. Biotechnol Prog (2006) 0.98
Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties. J Biol Chem (2010) 0.98
Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. Nucl Med Biol (2010) 0.98
Directed evolution for improved secretion of cancer-testis antigen NY-ESO-1 from yeast. Protein Expr Purif (2006) 0.98
Degradation of mutated bovine pancreatic trypsin inhibitor in the yeast vacuole suggests post-endoplasmic reticulum protein quality control. J Biol Chem (2004) 0.97
Interleukin-2 mutants with enhanced alpha-receptor subunit binding affinity. Protein Eng (2003) 0.95
Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells. J Immunol (2012) 0.94
High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice. MAbs (2015) 0.94
Effect of small-molecule-binding affinity on tumor uptake in vivo: a systematic study using a pretargeted bispecific antibody. Mol Cancer Ther (2012) 0.94
Epidermal growth factor receptor downregulation by small heterodimeric binding proteins. Protein Eng Des Sel (2011) 0.91
Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeast. J Mol Biol (2012) 0.91
Antigen release kinetics in the phagosome are critical to cross-presentation efficiency. J Immunol (2008) 0.91
Contrasting secretory processing of simultaneously expressed heterologous proteins in Saccharomyces cerevisiae. Biotechnol Bioeng (2006) 0.91
Cutting edge: delay and reversal of T cell tolerance by intratumoral injection of antigen-loaded dendritic cells in an autochthonous tumor model. J Immunol (2010) 0.90
The full amino acid repertoire is superior to serine/tyrosine for selection of high affinity immunoglobulin G binders from the fibronectin scaffold. Protein Eng Des Sel (2010) 0.88
A disulfide-free single-domain V(L) intrabody with blocking activity towards huntingtin reveals a novel mode of epitope recognition. J Mol Biol (2011) 0.88
Peptide tags for enhanced cellular and protein adhesion to single-crystalline sapphire. Biotechnol Bioeng (2007) 0.88
Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy. Mol Imaging Biol (2011) 0.88
Engineering fibronectin-based binding proteins by yeast surface display. Methods Enzymol (2013) 0.88
Probing the interface between biomolecules and inorganic materials using yeast surface display and genetic engineering. Acta Biomater (2005) 0.88
Protein Engineering and Selection Using Yeast Surface Display. Methods Mol Biol (2015) 0.88
Engineered interleukin-2 antagonists for the inhibition of regulatory T cells. J Immunother (2009) 0.87
Context-dependent mutations predominate in an engineered high-affinity single chain antibody fragment. Protein Sci (2006) 0.86
Determination of 35 cell surface antigen levels in malignant pleural effusions identifies CD24 as a marker of disseminated tumor cells. Int J Cancer (2013) 0.86
A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. Protein Eng Des Sel (2012) 0.85
Zebrafish brd2a and brd2b are paralogous members of the bromodomain-ET (BET) family of transcriptional coregulators that show structural and expression divergence. BMC Dev Biol (2008) 0.84
Rolling adhesion kinematics of yeast engineered to express selectins. Biotechnol Prog (2003) 0.83
Targeted cytolysins synergistically potentiate cytoplasmic delivery of gelonin immunotoxin. Mol Cancer Ther (2013) 0.82
A high affinity human antibody antagonist of P-selectin mediated rolling. Biochem Biophys Res Commun (2006) 0.81
Protein engineering for therapeutics, part B. Preface. Methods Enzymol (2012) 0.81
Activation of tolerogenic dendritic cells in the tumor draining lymph nodes by CD8+ T cells engineered to express CD40 ligand. J Immunol (2010) 0.80
Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits. Integr Biol (Camb) (2014) 0.79
Single cells from human primary colorectal tumors exhibit polyfunctional heterogeneity in secretions of ELR+ CXC chemokines. Integr Biol (Camb) (2013) 0.78
Exploiting bias in a non-immune human antibody library to predict antigenicity. Protein Eng Des Sel (2011) 0.78
Synergistic antitumor activity from two-stage delivery of targeted toxins and endosome-disrupting nanoparticles. Biomacromolecules (2013) 0.77
Protein engineering for therapeutics, Part A. Preface. Methods Enzymol (2012) 0.76
Protein technologies. Curr Opin Biotechnol (2007) 0.76
CD8+ T-cell responses rapidly select for antigen-negative tumor cells in the prostate. Cancer Immunol Res (2013) 0.75
Single-chain antibody fragment-based adsorbent for the extracorporeal removal of beta2-microglobulin. Kidney Int (2004) 0.75
Jay Bailey as mentor--the students' perspective. Biotechnol Bioeng (2002) 0.75